Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells in multiple myeloma: the issue of safety.
S
S
Sica
F
F
Sorá
P
P
Chiusolo
S
S
Cicconi
N
N
Piccirillo
P
P
Cattani
L
L
Laurenti
G
G
Leone
D018952:Antigens, CD34 / Q000032:analysis; D002454:Cell Differentiation; D019070:Cell Lineage; D002469:Cell Separation; D003586:Cytomegalovirus Infections / Q000453:epidemiology / Q000209:etiology*; D004198:Disease Susceptibility; D006085:Graft Survival; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006412:Hematopoietic Stem Cells / Q000737:chemistry / Q000145:classification*; D006801:Humans; D015994:Incidence; D009101:Multiple Myeloma / Q000628:therapy*; D012306:Risk; D016176:T-Lymphocyte Subsets / Q000166:cytology*; D018800:Thy-1 Antigens / Q000032:analysis; D014182:Transplantation, Autologous
D018952:Antigens, CD34; D018800:Thy-1 Antigens